TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38807515

Group type: EXPERIMENTAL
Intervention: 50 U RTU abobotulinumtoxinA
Number of subjects: 150

Group type: COMPARATOR
Intervention: 20 U powder BoNT-A
Number of subjects: 150
Study: 38807643

Group type: EXPERIMENTAL
Intervention: BPD-DS
Number of subjects: 215

Group type: COMPARATOR
Intervention: RYGB
Number of subjects: 215

Group type: COMPARATOR
Intervention: SG
Number of subjects: 215
Study: 38807685

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 114

Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 114
Study: 38807691

Group type: EXPERIMENTAL
Intervention: Online Mindfulness-Based Program (MBP) for parents, 28 days duration, including 20 psychoeducation videos, homework audio guidance, and four instructor-led online group meetings
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Online Mindfulness-Based Program (MBP) for parents
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waitlist Control Group
Number of subjects: 43
Study: 38807948

Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM) in addition to standard post-MI treatment
Number of subjects: 790

Group type: COMPARATOR
Intervention: Standard post-MI treatment without ICM
Number of subjects: 790
Study: 38807990

Group type: EXPERIMENTAL
Intervention: Live coaching with video-based exercise and mixed reality technology-driven exercise
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 128
Study: 38808136

Group type: EXPERIMENTAL
Intervention: AGT103-T treatment during ATI
Number of subjects: 6
Study: 38808265

Group type: EXPERIMENTAL
Intervention: Nordic walking (NW) training group (n=14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Free walking (FW) training group (n=14)
Number of subjects: 28
Study: 38808319

Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride 1000mg extended release once daily for 24 weeks in addition to standard-of-care WHO MB multidrug therapy (MDT) during 48 weeks.
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo for 24 weeks in addition to standard-of-care WHO MB multidrug therapy (MDT) during 48 weeks.
Number of subjects: 166
Study: 38808361

Group type: EXPERIMENTAL
Intervention: SCG101 T-cell therapy
Number of subjects: 1
Study: 38808476

Group type: EXPERIMENTAL
Intervention: Oral semaglutide (3 mg escalating to 14 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 38808490

Group type: EXPERIMENTAL
Intervention: Esketamine (0.2 mg/kg infused intravenously over 40 minutes after childbirth)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo (infused intravenously over 40 minutes after childbirth)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Esketamine
Number of subjects: 364
Study: 38809014

Group type: EXPERIMENTAL
Intervention: Web-based telemonitoring group
Number of subjects: 94

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 94
Study: 38809056

Group type: EXPERIMENTAL
Intervention: TREM-1 as a biomarker for diagnosis of kidney disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TREM-1 as a potential therapeutic target
Number of subjects: 0
Study: 38809105

Group type: EXPERIMENTAL
Intervention: Community-based walking intervention for 3 months
Number of subjects: 366
Study: 38809148

Group type: EXPERIMENTAL
Intervention: Automated nnU-Net-based segmentation of abdominal organs using quantitative water-fat MRI
Number of subjects: 127
Study: 38809174

Group type: EXPERIMENTAL
Intervention: Zodasiran 50 mg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Zodasiran 100 mg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Zodasiran 200 mg
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 38809322

Group type: EXPERIMENTAL
Intervention: MittEcho Measurement Feedback System (MFS)
Number of subjects: 701
Study: 38809323

Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (NO)
Number of subjects: 14
Study: 38809537

Group type: EXPERIMENTAL
Intervention: Stomach-preserving surgery
Number of subjects: 451

Group type: COMPARATOR
Intervention: Standard gastrectomy
Number of subjects: 451
Study: 38809547

Group type: EXPERIMENTAL
Intervention: CLAD/LDAC/Ven
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intensive chemotherapy
Number of subjects: 35
Study: 38809554

Group type: EXPERIMENTAL
Intervention: Direct-to-consumer educational brochure (intervention group)
Number of subjects: 4225

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 4225
Study: 38809606

Group type: EXPERIMENTAL
Intervention: Symptom-checker (SMASS) for self-triage
Number of subjects: 2543
Study: 38809849

Group type: EXPERIMENTAL
Intervention: Benfotiamine (600 mg or 1200 mg)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Benfotiamine (selected dose from phase 2A)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study: 38809909

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Number of subjects: 153

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 153
Study: 38809948

Group type: EXPERIMENTAL
Intervention: Exergame-based motor-cognitive training with resonance breathing guided by heart-rate variability biofeedback (HRV-BF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 38810010

Group type: EXPERIMENTAL
Intervention: Remote self-measured blood pressure (SMBP) program with Bluetooth-enabled blood pressure cuff
Number of subjects: 119

Group type: COMPARATOR
Intervention: Remote self-measured blood pressure (SMBP) program with manual entry
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Remote SMBP program
Number of subjects: 119
Study: 38810093

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study: 38810172

Group type: EXPERIMENTAL
Intervention: Fetal antiseizure medication (ASM) exposure
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group (children of healthy women)
Number of subjects: 324
Study: 38810208

Group type: EXPERIMENTAL
Intervention: Open radical hysterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimally invasive radical hysterectomy
Number of subjects: 0
Study: 38810255

Group type: EXPERIMENTAL
Intervention: Step-by-Step (SbS) digital mental health intervention
Number of subjects: 1249

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 1249
Study: 38810556

Group type: EXPERIMENTAL
Intervention: Add-on astragalus for 48 weeks
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 118
Study: 38810600

Group type: EXPERIMENTAL
Intervention: Eculizumab (weekly induction of 600 mg or 900 mg followed by maintenance doses of 300 to 1200 mg every two weeks for up to 26 weeks)
Number of subjects: 11
Study: 38810699

Group type: EXPERIMENTAL
Intervention: ESC-2014
Number of subjects: 5036

Group type: EXPERIMENTAL
Intervention: ESC-2019
Number of subjects: 5036

Group type: EXPERIMENTAL
Intervention: TELOS
Number of subjects: 5036

Group type: EXPERIMENTAL
Intervention: PEITHO
Number of subjects: 5036

Group type: EXPERIMENTAL
Intervention: Bova
Number of subjects: 5036

Group type: EXPERIMENTAL
Intervention: NEWS2
Number of subjects: 5036

Group type: EXPERIMENTAL
Intervention: FAST
Number of subjects: 5036
Study: 38810921

Group type: EXPERIMENTAL
Intervention: Personalized screening method
Number of subjects: 474

Group type: COMPARATOR
Intervention: Traditional screening
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Personalized screening
Number of subjects: 474
Study: 38810968

Group type: EXPERIMENTAL
Intervention: Modified NHL-BFM-95 protocol combined with anaplastic lymphoma kinase inhibitor
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Modified NHL-BFM-95 protocol combined with vinblastine (VBL)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Anaplastic lymphoma kinase inhibitor maintenance therapy
Number of subjects: 136

Group type: COMPARATOR
Intervention: Low-risk group (R1)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Intermediate-risk group (R2)
Number of subjects: 136

Group type: COMPARATOR
Intervention: High-risk group (R3)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Patients with MDD (+)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Patients with stage IV cancer
Number of subjects: 136

Group type: COMPARATOR
Intervention: Patients with SC/LH lymphoma
Number of subjects: 136

Group type: COMPARATOR
Intervention: Patients with high-risk sites
Number of subjects: 136
Study: 38811045

Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil (iTRE) up to 12 breaths (72 µg) 4 times daily
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 38811104

Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI
Number of subjects: 1639

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1639

Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI (optimized)
Number of subjects: 1639

Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI (unoptimized)
Number of subjects: 1639
Study: 38811107

Group type: EXPERIMENTAL
Intervention: Stage 0 cardiac damage (women: 2.6%, men: 3.1%)
Number of subjects: 2026

Group type: EXPERIMENTAL
Intervention: Stage 1 cardiac damage (women: 13.4%, men: 10.1%)
Number of subjects: 2026

Group type: EXPERIMENTAL
Intervention: Stage 2 cardiac damage (women: 37.1%, men: 39.5%)
Number of subjects: 2026

Group type: EXPERIMENTAL
Intervention: Stage 3 cardiac damage (women: 27.5%, men: 15.6%)
Number of subjects: 2026

Group type: EXPERIMENTAL
Intervention: Stage 4 cardiac damage (women: 19.4%, men: 31.7%)
Number of subjects: 2026
Study: 38811250

Group type: EXPERIMENTAL
Intervention: Hematuria Cancer Risk Score (HCRS) with Renal Bladder Ultrasound (RBUS)
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: HCRS with RBUS
Number of subjects: 2484
Study: 38811492

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50-200 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV)
Number of subjects: 0
Study: 38811502

Group type: EXPERIMENTAL
Intervention: Esophageal self-dilation therapy (ESDT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: ESDT
Number of subjects: 25
Study: 38811554

Group type: EXPERIMENTAL
Intervention: Combination bevacizumab (BVZ) therapy
Number of subjects: 74
Study: 38811871

Group type: EXPERIMENTAL
Intervention: MAXPOWER Biological Antibacterial Liquid
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 38811888

Group type: EXPERIMENTAL
Intervention: IMT with 30% MIP
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: IMT with 60% MIP
Number of subjects: 47

Group type: COMPARATOR
Intervention: IMT with 10% MIP
Number of subjects: 47
Study: 38811911

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with 2.5 mg/ml ropivacaine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 64
Study: 38811947

Group type: EXPERIMENTAL
Intervention: Field-deployed ATSB stations
Number of subjects: 71

Group type: COMPARATOR
Intervention: Non-deployed ATSB stations
Number of subjects: 71
Study: 38811974

Group type: EXPERIMENTAL
Intervention: COVID-19 lockdowns
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Subgroup of overweight and obese children
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Subgroup of normal-weight children
Number of subjects: 256

Group type: COMPARATOR
Intervention: Comparison to German reference population
Number of subjects: 256

Group type: COMPARATOR
Intervention: U8 to U9 examinations
Number of subjects: 256
Study: 38811985

Group type: EXPERIMENTAL
Intervention: Lumbar spinal manipulation (SMT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Deactivated ultrasound (control)
Number of subjects: 55
Study: 38811992

Group type: EXPERIMENTAL
Intervention: D + T + EP
Number of subjects: 805

Group type: COMPARATOR
Intervention: D + EP
Number of subjects: 805

Group type: COMPARATOR
Intervention: EP
Number of subjects: 805
Study: 38811998

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor based treatment (empagliflozin and linagliptin)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-SGLT2 inhibitor based treatment (metformin and insulin)
Number of subjects: 65
Study: 38812037

Group type: EXPERIMENTAL
Intervention: SPARC
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: LDLJ
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: TDSM
Number of subjects: 31
Study: 38812047

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Lifestyle + medical food
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control
Number of subjects: 93
Study: 38812073

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) supported teleaudiology hearing aid services
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-Community Health Worker (non-CHW) group
Number of subjects: 28
Study: 38812378

Group type: EXPERIMENTAL
Intervention: Hand Task (HT) group - 45 minutes of task-oriented training with robotic hand for 20 sessions
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (CON) group - 45 minutes of hand-functional exercises without objects using the same robot
Number of subjects: 34
Study: 38812507

Group type: EXPERIMENTAL
Intervention: Vaccinated with two doses of CoronaVac, 2 to 8 weeks post-infection
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection in the pediatric population vaccinated with an inactivated SARS-CoV-2 vaccine
Number of subjects: 12
Study: 38812955

Group type: EXPERIMENTAL
Intervention: Full app containing all intervention modules
Number of subjects: 761

Group type: COMPARATOR
Intervention: Educational only app containing only the educational content
Number of subjects: 761
Study: 38813112

Group type: EXPERIMENTAL
Intervention: Fexagratinib 80 mg bd on a continuous schedule until disease progression or unacceptable toxicity
Number of subjects: 12
Study: 38813261

Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR) in persons with HIV (PWH)
Number of subjects: 39
Study: 38813388

Group type: EXPERIMENTAL
Intervention: EDP1815 (1 capsule daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EDP1815 (4 capsules daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EDP1815 (10 capsules daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38813446

Group type: EXPERIMENTAL
Intervention: Vosoritide (15 μg/kg/day, daily subcutaneous injection)
Number of subjects: 26
Study: 38813444

Group type: EXPERIMENTAL
Intervention: Dietary supplement (blueberry juice and extract, tryptophan 2 g, tyrosine 10 g)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (identical appearing inert substance)
Number of subjects: 103
Study: 38813551

Group type: EXPERIMENTAL
Intervention: R21/Matrix-M™ vaccine at varied doses (10µgR21/50 µg Matrix-M™, 5µgR21/25µg Matrix-M™, 5µgR21/50µg Matrix-M™)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: R21/Matrix-M™ vaccine
Number of subjects: 91
Study: 38813815

Group type: EXPERIMENTAL
Intervention: ML GSP model based on clinical and CT image features
Number of subjects: 301

Group type: COMPARATOR
Intervention: Radiomics model
Number of subjects: 301
Study: 38813838

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (onabotA) treatment
Number of subjects: 744
Study: 38813933

Group type: EXPERIMENTAL
Intervention: Sealer-based obturation technique (SBO) with calcium silicate sealer (CSS)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Warm-vertical compaction (WVC) with resin-based sealer (RBS)
Number of subjects: 194
Study: 38813962

Group type: COMPARATOR
Intervention: Above-elbow cast
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Above/below-elbow cast
Number of subjects: 97

Group type: COMPARATOR
Intervention: Malunion group
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: No malunion group
Number of subjects: 97
Study: 38814000

Group type: EXPERIMENTAL
Intervention: Acute bronchodilation treatment, specific details not available.
Number of subjects: 0
Study: 38814132

Group type: COMPARATOR
Intervention: Daridorexant 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daridorexant 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study: 38814264

Group type: EXPERIMENTAL
Intervention: 5-hydroxymethylcytosine (5hmC) biomarkers in circulating cell-free DNA (cfDNA)
Number of subjects: 2576
Study: 38814343

Group type: EXPERIMENTAL
Intervention: Pre-treatment serum histidine concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-treatment serum glutamate concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-treatment serum phenylalanine concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-treatment serum tyrosine concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-treatment serum valine concentration
Number of subjects: 0
Study: 38814433

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) 80 mg every 4 weeks (Q4W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) 80 mg every 2 weeks (Q2W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study: 38814525

Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) with FARAPULSE™ system
Number of subjects: 752

Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 752
Study: 38814532

Group type: EXPERIMENTAL
Intervention: Troriluzole
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 38814627

Group type: EXPERIMENTAL
Intervention: Lay health worker-led advance care planning intervention
Number of subjects: 213

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 213
Study: 38814681

Group type: EXPERIMENTAL
Intervention: Mental health chatbot app (Wysa) used over a period of 4 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Mental health chatbot app (Wysa)
Number of subjects: 68
Study: 38814692

Group type: EXPERIMENTAL
Intervention: CONSORT invitations via automated confidential SMS text messages
Number of subjects: 600

Group type: COMPARATOR
Intervention: Physical invitation cards alone
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: CONSORT intervention
Number of subjects: 600
Study: 38814736

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biologics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of OIT and biologics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other biologics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New therapeutic strategies
Number of subjects: 0
Study: 38814827

Group type: EXPERIMENTAL
Intervention: ANNE sensors (multimodal, wireless wearable sensor system)
Number of subjects: 76

Group type: COMPARATOR
Intervention: ApneaLink Air (standard home sleep apnea test)
Number of subjects: 76
Study: 38815111

Group type: EXPERIMENTAL
Intervention: Unflavored, sucralose-sweetened electronic cigarette
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combustible cigarettes
Number of subjects: 0
Study: 38815151

Group type: EXPERIMENTAL
Intervention: Olaparib, starting dose of 135 mg/m2/dose, administered twice daily for 28-day cycles.
Number of subjects: 18
Study: 38815152

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 730

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 730
Study: 38815164

Group type: EXPERIMENTAL
Intervention: Statistical surveillance of microbiology data
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Statistical surveillance of microbiology data (pre-pandemic)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Statistical surveillance of microbiology data (pandemic)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (without alerting infection prevention programs)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (pre-pandemic)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (pandemic)
Number of subjects: 82
Study: 38815173

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU) four times daily for 8 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 61
Study: 38815178

Group type: EXPERIMENTAL
Intervention: Clonal hematopoiesis-associated mutations (CHm) identified through liquid biopsy
Number of subjects: 255
Study: 38815188

Group type: EXPERIMENTAL
Intervention: REDCap Clinical Data Interoperability Services (CDIS) module
Number of subjects: 73

Group type: COMPARATOR
Intervention: EHR relational databases (UChicago's Clinical Research Data Warehouse and VUMC's Epic Clarity database)
Number of subjects: 73
Study: 38815230

Group type: EXPERIMENTAL
Intervention: Individualized Pain Plans (IPPs) implemented in the emergency department
Number of subjects: 153

Group type: COMPARATOR
Intervention: Baseline comfort managing VOEs
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Post-IPP implementation comfort managing VOEs
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Ordering of recommended medication by providers
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Intention to use IPPs by providers
Number of subjects: 153
Study: 38815694

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with 50-60 Gy in 5-8 fractions, using online magnetic resonance (MR) image-guidance on a 1.5 T MRI-linac.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 28
Study: 38815760

Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Anhedonia
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Both forms of psychotherapy
Number of subjects: 116
Study: 38815756

Group type: EXPERIMENTAL
Intervention: COVID-19 plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: RNA aptamer that neutralizes histones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EVs isolated from COVID-19 plasma
Number of subjects: 0